कोशिश गोल्ड - मुक्त

A dose of AI

Business Standard

|

July 02, 2025

From detecting cancer to reshaping diagnosis and treatment, artificial intelligence is changing the DNA of health care with the promise of a 'healthier human'. The second of a three-part series

- SHELLEY SINGH

A dose of AI

In early 2024, Marly Garnreiter, a 27-year-old French woman, began experiencing persistent night sweats and itchy skin. Her doctors dismissed it as stress. Her blood report came back normal. Out of curiosity, she asked ChatGPT about it. The artificial intelligence (AI) chatbot suggested she might have blood cancer. Nearly a year later, in April 2025, doctors confirmed she had Hodgkin's lymphoma, a cancer that affects the lymphatic system.

Stories like Garnreiter's are making headlines repeatedly: AI catching what humans miss.

While anecdotal, they point to a shift underway in health care—one where AI doesn't replace doctors but sharpens their eyes and expands their reach. And also, frees up the time doctors and nurses spend on tasks like writing patient summaries, current patient condition, treatment plan, and so on.

Discharge summaries and reports, too, are being prepared by AI and sent to patients, after a human has crosschecked them for errors.

"The future lies in human-AI collaboration, where technology enhances our diagnostic and therapeutic capabilities," says Bharat Aggarwal, principal director, radiology services, Max Super Speciality Hospital, Saket, Delhi. The hospital chain is implementing AI in 'shadow mode', running predictions alongside human clinicians to verify accuracy before actual deployment.

"AI is reshaping the healthcare landscape at a brisk pace," says Venkatesh Krishnan, executive director, public sector, health care, education, Microsoft India and South Asia. "Globally, 79 per cent of health care and lifesciences companies are leveraging AI to drive better outcomes." In India, he says, this momentum is visible as healthcare systems navigate workforce challenges, rising patient expectations, and need for personalized care.

Business Standard से और कहानियाँ

Business Standard

Labour Codes impact: HCL tech profit slips 11%

Q3 top line beats Street estimates, bottom line misses expectations

time to read

2 mins

January 13, 2026

Business Standard

New labour Codes, restructuring weigh on TCS earnings

Tata Consultancy Services (TCS), India’s largest information technology (IT) services firm, saw its profit impacted in the October-December quarter by restructuring and changes in labour Codes.

time to read

1 min

January 13, 2026

Business Standard

Business Standard

Black drives the thrill for car buyers

Sees a surge in yearly sales, while white remains practical 'utility king'

time to read

2 mins

January 13, 2026

Business Standard

CHOOSING THE RIGHT B-SCHOOL TO MATCH YOUR CAREER GOALS

Success comes when you pick an institution that fits your professional dreams and your personality, helping you become the leader you want to be

time to read

2 mins

January 13, 2026

Business Standard

Business Standard

China’s PVC rethink to help India pipe makers

Supply likely to tighten after S-PVC rebate withdrawal

time to read

2 mins

January 13, 2026

Business Standard

Responsible growth

India must ensure data centres are sustainable

time to read

2 mins

January 13, 2026

Business Standard

India’s GenZ is full of creativity: PM

Prime Minister Narendra Modi on Monday said India's GenZ is full of creativity and with innovative ideas, energy and purpose, the country’s youth is at the forefront of nation-building.

time to read

1 min

January 13, 2026

Business Standard

Business Standard

Iran wants to negotiate after threats to attack, says Trump

At least 572 killed in protests; Tehran says situation ‘under full control’

time to read

2 mins

January 13, 2026

Business Standard

Insurers knock on Irdai door for clarity on director overlap ban

CLAUSE THREATENS BOARD STRUCTURES AT BANK-BACKED FIRMS SAYS INDUSTRY

time to read

2 mins

January 13, 2026

Business Standard

Delhi HC allows Zydus to sell generic version of cancer drug

Citing public interest, the Delhi High Court has cleared the way for Zydus Life-sciences to proceed with the sale of its version of the cancer drug nivolumab in India.

time to read

1 min

January 13, 2026

Listen

Translate

Share

-
+

Change font size